HealthNotableSingle-sourceDeveloping
5.4
Novo Nordisk sues Eli Lilly over alleged false advertising in weight loss drug marketing
Valor Econômico·US · DK·2 days ago
Novo Nordisk has initiated legal action in the US alleging that Eli Lilly's advertising for its obesity medication contains misleading claims. The litigation highlights intensifying competition in the GLP-1 market as both firms vie for dominance in the high-growth weight-loss drug sector.
Locations
Entities